The estimated Net Worth of Hui Liu is at least $9.23 Milion dollars as of 6 April 2023. Hui Liu owns over 98,085 units of Merus N.V stock worth over $7,844,484 and over the last 5 years he sold MRUS stock worth over $0. In addition, he makes $1,382,530 as Chief Business Officer and Head of Merus U.S. at Merus N.V.
Hui has made over 14 trades of the Merus N.V stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 98,085 units of MRUS stock worth $770,948 on 6 April 2023.
The largest trade he's ever made was exercising 98,085 units of Merus N.V stock on 6 April 2023 worth over $770,948. On average, Hui trades about 5,282 units every 59 days since 2020. As of 6 April 2023 he still owns at least 156,016 units of Merus N.V stock.
You can see the complete history of Hui Liu stock trades at the bottom of the page.
Dr. Hui Liu Ph.D. serves as Chief Business Officer and Head of Merus U.S. of the Company. His responsibilities include all aspects of business development, including in- and out- licensing, acquisitions and alliance management. Table of Contents Prior to joining Merus, Dr. Liu served as Vice President and Global Head, Business Development & Licensing, Oncology at Novartis AG, a pharmaceutical company, from 2013 to 2015, and as Vice President and Global Head, Business Development & Licensing, Vaccines & Diagnostics, from 2009 to 2012. Prior to Novartis, Dr. Liu held various management positions at Pfizer, Inc., a pharmaceutical company, from 2004 to 2009 and at Pfizer, Inc. and its predecessor company Warner-Lambert from 1997 to 2001. From 2001 to 2004, Dr. Liu was an investment banker at Goldman Sachs and Citigroup. Dr. Liu holds a Ph.D. in molecular biology and an M.B.A. in finance from the University of Michigan and a B.S. in biology from Peking University.
As the Chief Business Officer and Head of Merus U.S. of Merus N.V, the total compensation of Hui Liu at Merus N.V is $1,382,530. There are no executives at Merus N.V getting paid more.
Hui Liu is 47, he's been the Chief Business Officer and Head of Merus U.S. of Merus N.V since 2018. There are 13 older and 3 younger executives at Merus N.V. The oldest executive at Merus N.V is Gregory Perry, 59, who is the Independent Non-Executive Vice Chairman of the Board.
Hui's mailing address filed with the SEC is C/O MERUS N.V., UPPSALALAAN 17, UTRECHT, P7, 3584 CT.
Over the last 5 years, insiders at Merus N.V have traded over $76,701,272 worth of Merus N.V stock and bought 4,110,523 units worth $71,063,751 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... a Corp Incyte. On average, Merus N.V executives and independent directors trade stock every 18 days with the average trade being worth of $4,323,728. The most recent stock trade was executed by Harry Shuman on 20 August 2024, trading 5,000 units of MRUS stock currently worth $251,400.
merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Merus N.V executives and other stock owners filed with the SEC include: